Rocket Lab Turns Up the Heat: SpaceX IPO Countdown Meets Neutron Rocket Progress

The commercial space race is entering a new phase, and Rocket Lab is positioning itself as the go-to publicly traded vehicle for investors who want exposure before SpaceX’s landmark listing. The stock surged 5.52% on the latest session to €103.20, recovering from a choppy week as two powerful catalysts converge: a multibillion-dollar SpaceX debut on June 12 and the steady advance of Rocket Lab’s own Neutron rocket, slated for its first flight in the fourth quarter of 2026.

Institutional investors are placing their bets accordingly. Ownership among big-money players now stands at roughly 72% of outstanding shares, a level that signals structural conviction rather than speculative froth. Vanguard recently expanded its stake by 13.4% to 47.4 million shares, while the Swiss National Bank boosted its position by a whopping 67.7%. CIBC Asset Management joined the pack with an increase of more than a third. These moves reflect a belief that Rocket Lab has the infrastructure and execution capability to rival only SpaceX in achieving reliable launch scale — a narrative CEO Peter Beck frequently emphasizes.

Wall Street analysts have taken notice. The consensus rating sits at "Moderate Buy," with an average price target near $99. Yet several houses see far more upside. New Street Research targets $150, Stifel looks for $132, and Deutsche Bank, TD Cowen, and Needham each pin a $120 price tag on the stock. Given that shares currently trade about 20% above their 50-day moving average — which sits at €85.20 — the relative strength index of 51 suggests the rally hasn't become overheated despite a year-to-date gain of nearly 59%.

Should investors sell immediately? Or is it worth buying Rocket Lab?

The numbers back the optimism. Rocket Lab reported first-quarter revenue of $200.35 million, a 63.4% jump from the prior year and a record for the company. Its market capitalization now stands at roughly $65.8 billion, while debt is negligible at a debt-to-equity ratio of 0.02. That financial health provides a cushion for the capital-intensive development of Neutron, a medium-lift rocket designed to go head-to-head with SpaceX’s Falcon 9. A key edge: each Neutron launch is expected to cost about $15 million less than a Falcon mission, a margin that could sway commercial and government customers. A multi-million-dollar test-flight contract from defense tech firm Anduril adds further validation.

Competitors are stumbling, which only sharpens Rocket Lab’s appeal. On June 5, a Blue Origin New Glenn rocket exploded during a test, highlighting the difficulty of bringing new hardware online. Against that backdrop, institutional investors are increasingly using Rocket Lab as a stable proxy for the burgeoning space economy. Insider selling, meanwhile, has been orderly: approximately $67 million in shares changed hands from insiders over the past 90 days, all through pre-planned 10b5-1 programs tied to tax obligations from equity vesting — a routine practice for high-growth tech companies.

All eyes now turn to June 12, when SpaceX is expected to debut with a valuation of $1.75 trillion. That listing is likely to shine a spotlight on the entire sector, and Rocket Lab — as the only publicly traded pure-play with comparable infrastructure — stands ready to capture the spillover. With Neutron’s first flight on the horizon and a quarterly report that reinforces the growth story, the stock could soon challenge its old high of €133.80.

Ad

Rocket Lab Stock: New Analysis - 9 June

Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Rocket Lab analysis...

en | US7731211089 | ROCKET | boerse | 69508892 |